Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Egetis Therapeutics ABSTU:P0F +0.34%51 Cyclically Adjusted PS Ratio is 11.66 as of Jul. 28, 2026, which is 45% above its 10-year median of 8.05. GuruFocus rates STU:P0F with a GF Score™ of 51/100 and a GF Value™ of €0.48 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 537 Biotechnology companies, Egetis Therapeutics AB ranks worse than 70.2% on this metric.
The historical rank and industry rank for Egetis Therapeutics AB's Cyclically Adjusted PS Ratio or its related term are showing as below:
STU:P0F'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 4.3 Med: 8.05 Max: 27.37
Current: 12.48
During the past years, Egetis Therapeutics AB's highest Cyclically Adjusted PS Ratio was 27.37. The lowest was 4.30. And the median was 8.05.
STU:P0F's Cyclically Adjusted PS Ratio is ranked worse than 70.2% of 537
companies
in the Biotechnology industry
Industry Median: 5.63
vs STU:P0F: 12.48
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Egetis Therapeutics AB's adjusted revenue per share data for the three months ended in Mar. 2026 was €0.003. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €0.05 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Egetis Therapeutics AB (STU:P0F) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Egetis Therapeutics AB Cyclically Adjusted PS Ratio Related Terms
Egetis Therapeutics AB Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Egetis Therapeutics AB's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egetis Therapeutics AB Cyclically Adjusted PS Ratio Chart
STU:P0F vs VRTX, REGN, RVMD: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, Egetis Therapeutics AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egetis Therapeutics AB Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Egetis Therapeutics AB's Cyclically Adjusted PS Ratio falls into.
Egetis Therapeutics AB Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 11.66 mean?
Egetis Therapeutics AB (STU:P0F) has a Cyclically Adjusted PS Ratio of 11.66 as of Jul. 28, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Egetis Therapeutics AB and its competitors. This is 45% above median its historical median of 8.05. Over the past decade, Egetis Therapeutics AB's Cyclically Adjusted PS Ratio has ranged from 4.30 to 27.37. According to the industry distribution chart, Egetis Therapeutics AB ranks #377 out of 537 companies in the Biotechnology industry, placing it in the top 70.2%.
Is Egetis Therapeutics AB's Cyclically Adjusted PS Ratio too high?
Egetis Therapeutics AB's current Cyclically Adjusted PS Ratio of 11.66 is 45% above median its 10-year median of 8.05. Over the past 10 years, this metric has ranged from a low of 4.30 to a high of 27.37. The Biotechnology industry median Cyclically Adjusted PS Ratio is 5.63. Egetis Therapeutics AB's value of 11.66 is 107.1% above this industry median. Based on the distribution chart, Egetis Therapeutics AB ranks #377 out of 537 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Egetis Therapeutics AB has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egetis Therapeutics AB's Cyclically Adjusted PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Egetis Therapeutics AB ranks #377 out of 537 companies for Cyclically Adjusted PS Ratio. This places Egetis Therapeutics AB in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 5.63. Egetis Therapeutics AB's value of 11.66 is 107.1% above this benchmark. Historically, Egetis Therapeutics AB's own Cyclically Adjusted PS Ratio has ranged from 4.30 to 27.37 over the past decade. While the company's 10-year median is 8.05 vs. the industry median of 5.63, Egetis Therapeutics AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.63, based on 537 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Egetis Therapeutics AB's current Cyclically Adjusted PS Ratio of 11.66 is 107.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Egetis Therapeutics AB and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Egetis Therapeutics AB's current Cyclically Adjusted PS Ratio is 11.66, which is 45% above median its own 10-year median of 8.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egetis Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, Egetis Therapeutics AB (STU:P0F) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.48, compared to a current price of €0.58 — trading 21.5% above its estimated fair value. The current Cyclically Adjusted PS Ratio is 11.66, which is 45% above median its 10-year median of 8.05 and 107.1% above the Biotechnology industry median of 5.63. Egetis Therapeutics AB's overall GF Score™ is 51/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Egetis Therapeutics AB (STU:P0F), the current Cyclically Adjusted PS Ratio is 11.66 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egetis Therapeutics AB (STU:P0F) Overvalued in 2026?
Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be overvalued.
The current stock price of €0.58 is trading 21.5% above its estimated GF Value™ of €0.48.
GuruFocus considers Egetis Therapeutics AB to be Modestly Overvalued.
Key valuation signals for STU:P0F:
Cyclically Adjusted PS Ratio: 11.66 (45% above median its 10-year median of 8.05)
GF Value™: €0.48 vs. price of €0.58 (21.5% above fair value)
Industry Position: 107.1% above the Biotechnology median (#377 of 537)
No single metric tells the full story. See the STU:P0F stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
51GF Score
Get the complete analysis for STU:P0F
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:P0F has been successfully added to your 
